Edwin Rock
Chief Tech/Sci/R&D Officer at GLYCOMIMETICS, INC.
Net worth: 641 939 $ as of 30/04/2024
Profile
Edwin P.
Rock is currently the Chief Medical Officer & Senior Vice President at GlycoMimetics, Inc. Prior to this, he worked as the Chief Medical Officer at Partner Therapeutics, Inc. Dr. Rock received his undergraduate degree from Swarthmore College and his doctorate from Stanford University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0.58% | 15/03/2024 | 375,403 ( 0.58% ) | 641 939 $ | 30/04/2024 |
Edwin Rock active positions
| Companies | Position | Start |
|---|---|---|
| GLYCOMIMETICS, INC. | Chief Tech/Sci/R&D Officer | 06/09/2022 |
Former positions of Edwin Rock
| Companies | Position | End |
|---|---|---|
Partner Therapeutics, Inc.
 Partner Therapeutics, Inc. BiotechnologyHealth Technology Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | - |
Training of Edwin Rock
| Swarthmore College | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Partner Therapeutics, Inc.
Partner Therapeutics, Inc. BiotechnologyHealth Technology Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Edwin Rock
